Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2011-06-21
2011-06-21
Wilson, Michael C. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S006000
Reexamination Certificate
active
07964767
ABSTRACT:
Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced. Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.
REFERENCES:
patent: 5500346 (1996-03-01), Bright et al.
patent: 5849525 (1998-12-01), Hediger
patent: 6270978 (2001-08-01), Bright et al.
patent: 6713278 (2004-03-01), Bouvier et al.
patent: 2005/0004227 (2005-01-01), Saitoh
patent: 2005/0222391 (2005-10-01), Kodama et al.
patent: 2005/0281825 (2005-12-01), Kodama et al.
patent: 2006/0084119 (2006-04-01), Saitoh et al.
patent: 2006/0210569 (2006-09-01), Kodama et al.
patent: 9676557 (1997-06-01), None
patent: 1142473 (2001-10-01), None
patent: 1 514 928 (2005-03-01), None
patent: 1 731 032 (2006-12-01), None
patent: 6-261761 (1994-09-01), None
patent: 8-134100 (1996-05-01), None
patent: 11-000172 (1999-01-01), None
patent: 2001-197846 (2001-07-01), None
patent: 2001-139496 (2005-05-01), None
patent: 1999-0071666 (1999-09-01), None
patent: WO 97/19919 (1997-06-01), None
patent: WO 98/46777 (1998-10-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 03/033024 (2003-04-01), None
patent: WO 03/047621 (2003-06-01), None
patent: WO 03/083116 (2003-10-01), None
patent: WO 03/104453 (2003-12-01), None
Saitoh (J. Immunological Methods, 2007, vol. 332, p. 104-117).
Tsuchiya (Jan. 21, 2003, therapeutic antibody presentation, p. 1-21).
Mancini (1993, J. Med. Virol., vol. 39, p. 67-74).
D'Onofrie, “Making the case for acncer prevention in the schools”, Journal of School Health 59(5):225-227, 1989.
Inoue et al., “Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs”, Cancer Letters 230:72-80, 2005.
Pardee, “Tumor progression—targets for differential therapy”, Journal of Cellular Physiology 209(3):589-591, 2006 (abstract only).
ATCC Web Catalog, “Tumor Cell Lines” www.atcc.org (2007), 15 pages.
Basu et al., “Screening of Anti-PepT1 Antibodies Using Indirect ELISA,”Pharmaceutical Research, 13(9 Suppl.):S-37, Abstract No. APQ 1137 (1996).
Basu SK et al., “Development and Utility of Anti-PepT1 Anti-Peptide Polyclonal Antibodies”,Pharmaceutical Research, 15(2):338-342 (1998).
Blissard et al., “Baculovirus gp64 Gene Expression: Analysis of Sequences Modulating Early Transcription and Transactivation by IE1,”J. Virol., 65:5820-5827 (1991).
Blissard et al., “Location, Sequence, Transcriptional Mapping, and Temporal Expression of the gp64 Envelope Glycoprotein Gene of theOrgyia pseudotsugataMulticapsid Nuclear Polyhedrosis Virus,”Virology, 170:537-555 (1989).
Boublik et al., “Eukaryotic Virus Display: Engineering the major Surface Glycoprotein of the Autographa californica Nuclear Polyhedrosis Virus (ScNPV) for the Presentation of Foreign Proteins on the Virus Surface,”Biotechnology, 13: 1079-1084 (1995).
“Cancer Classification,” SEER Training Website, www.training.seer.cancer.gov/module—cancer—disease/unti3-categories2—by—histology (2005), 3 pages.
Friedman et al., “Characterization of the Intestinal Transport Parameters for Small Peptide Drugs,”J. Control. Release, 13:141-146 (1990).
Friedman et al., “Passive and Carrier-Mediated Intestinal Absorption Components of Two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril,”Pharm. Res., 6:1043-1047 (1989).
Ganapathy et al., “Proton-coupled solute transport in the animal cell plasma membrane,”Curr. Opin. Cell Biol., 3:695-701 (1991).
Garcia et al., “cDNA Cloning of MCT2, a Second Monocarboxylate Transporter Expressed in Different Cells than MCT1,”The Journal of Biological Chemistry, 270: 1843-1849 (1995).
Gonzalez et al., “An Oligopeptide Transporter is Expressed at High Levels in the Pancreatic Carcinoma Cell Lines AsPc-1 and Capan-2,”Cancer Res., 58(3): 519-525 (1998).
Grever et al., “The National Cancer Institute: Cancer Drug Discovery and Development Program,” Seminars in Oncology, 19(6): 622-638 (1992).
Hefferon et al., “Host Cell receptor Binding by Baculovirus GP64 and Kinetics of Virion Entry,”Virology, 258: 455-468 (1999).
Higgins, C.F., “ABC Transporters: From Microorganisms to Man,”Annu. Rev. Cell Biol., 8:67-113 (1992).
Houdebine, L.M., “Transgenic Animal Bioreactors,”Transgenic Res., 9: 305-320 (2000).
Hsu et al., “Overexpression of Human Intestinal Oligopeptide Transporter in Mammalian Cells via Adenoviral Transduction,”Pharm. Res., 15:1376-1381 (1998).
Kamada et al., “Generation of GP64-Expressing Mice and Induction of Tolerance to Budding Baculoviruses,”Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, Abstract No. 1PC-162, p. 659 (2003) (Translation Provided).
Karaki et al., “Production of anti-HLA class I alloantibodies using HLA-B51 transgenic mice,”Nihonmenekigakkaisoukai Gakujutsushuukaikiroku, Abstract No. C61, p. 197 (1990) (Translation Provided).
Knutter et al., “A Novel Inhibitor of the Mammalian Peptide Transporter PEPT1,”Biochemistry, 40(14):4454-4488 (2001).
Kolb et al., “Insertion of a Foreign Gene into the β-Casein Locus by Cre-Mediated Site-Specific Recombination,”Gene, 227: 21-31 (1999).
LaRiviere et al., “Transgenic Studies of Pain and Analgesia: Mutation of Background Genotype?”The Journal of Pharmacology and Experimental Therapeutics, 297: 467-473 (2001).
Lee et al., “Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1”,J. Control Release, 62(1-2):129-140 (1999).
Leiter, E.H., “Mice with Targeted Gene Disruptions of Gene Insertions for Diabetes Research: Problems, Pitfalls, and Potential Solutions,”Diabetologia, 45: 296-308 (2002).
Liang et al., “Human Intestinal H+/Peptide Cotransporter. Cloning, Functional Expression, and Chromosomal Localization,”J. Biol. Chem., 270:6456-6463 (1995).
Lindley et al., “Production of Monoclonal Antibodies Using Recombinant Baculovirus Displaying GP64-Fusion Proteins,”Journal of Immunological Methods, 234: 123-135 (2000).
Liu et al., “Molecular cloning of PEPT2, a new member of the H+/peptide cotransporter family, from human kidney,”Biochim. Biophys. Acta, 1235:461-466 (1995).
Loisel et al., “Recovery of homogeneous and functional α2-adrenergic receptors from extracellular baculovirus particles”,Nat Biotechnol, 15(12):1300-1304 (1997).
Lu et al., “Characterization of a Truncated Soluble Form of the Baculovirus (AcMNPV) Major Envelope Protein Gp64,”Protein Expression and Purification, 24: 196-201 (2002).
Mancini et al., “Induction of Anti-Hepatitis B Surface Antigen (HBsAg) Antibodies in HBsAg Producing Transgenic Mice: A Possible Way of Circumventing ‘Nonresponse’ to HBSAg,”Journal of Medical Virology, 39: 67-74 (1993).
Mangor et al., “A GP64-Null Baculovirus Pseudotyped with Vesicular Stomatitis Virus G Protein”,Journal of Virology, 75(6):2544-2556 (2001).
Mikhailov et al., “Expression of functionally active ATP-sensitive K-channels in insect cells using baculovirus”,FEBS Lett, 429(3):390-394 (1998).
Miyasaka et al., “Characterization of Human Taurine Transported Expressed in Insect Cells Using a Recombin
Jishage Kou-Ichi
Kamada Nobuo
Kodama Tatsuhiko
Yamada Yoshiki
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
Wilson Michael C.
LandOfFree
Transgenic mice expressing baculovirus soluble GP64 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mice expressing baculovirus soluble GP64 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mice expressing baculovirus soluble GP64 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696487